Predictive value of tumor-infiltrating lymphocytes for neoadjuvant therapy response in triple-negative breast cancer: A systematic review and meta-analysis

doi:10.5306/wjco.v15.i7.920

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 7

This Article

(163)

(142)

(0)

(19)

(4004)

(4)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Meta-Analysis

World J Clin Oncol. Jul 24, 2024; 15(7): 920-935
Published online Jul 24, 2024. doi: 10.5306/wjco.v15.i7.920

Full Size Figure Download Figure

Figure 1 PRISMA flow diagram for study selection of systematic review and meta-analysis. pCR: Pathological complete response; TIL: Tumor-infiltrating lymphocyte; TNBC: Triple-negative breast cancer.

Citation: Sun HK, Jiang WL, Zhang SL, Xu PC, Wei LM, Liu JB. Predictive value of tumor-infiltrating lymphocytes for neoadjuvant therapy response in triple-negative breast cancer: A systematic review and meta-analysis. World J Clin Oncol 2024; 15(7): 920-935
URL: https://www.wjgnet.com/2218-4333/full/v15/i7/920.htm
DOI: https://dx.doi.org/10.5306/wjco.v15.i7.920

Sun HK, Jiang WL, Zhang SL, Xu PC, Wei LM, Liu JB. Predictive value of tumor-infiltrating lymphocytes for neoadjuvant therapy response in triple-negative breast cancer: A systematic review and meta-analysis. World J Clin Oncol 2024; 15(7): 920-935 [PMID: 39071463 DOI: 10.5306/wjco.v15.i7.920]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.